Relay Therapeutics to Announce Q1 Earnings on May 5
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy RLAY?
Source: seekingalpha
- Earnings Announcement Schedule: Relay Therapeutics is set to release its Q1 2023 earnings report on May 5 after market close, with consensus EPS estimated at -$0.36 and revenue expected at $4.65 million, reflecting a significant 39.5% year-over-year decline, indicating challenges in the current market environment.
- Earnings Forecast Analysis: Over the past three months, EPS estimates have seen six upward revisions with no downward adjustments, suggesting cautious optimism among analysts regarding the company's future performance, although the overall revenue outlook remains weak, potentially impacting investor confidence.
- Market Focus: Ahead of the earnings report, Relay Therapeutics has garnered attention for its discussions on first-line breast cancer strategies and Zovegalisib triplet data, which could provide new momentum for the company's future growth prospects.
- Industry Rating Dynamics: According to Seeking Alpha's quant ratings, Relay Therapeutics and TNGX are highlighted as top picks ahead of Q1 earnings, indicating a positive market sentiment towards their potential performance, despite the current financial data warranting close scrutiny.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy RLAY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on RLAY
Wall Street analysts forecast RLAY stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 12.720
Low
13.00
Averages
14.75
High
17.00
Current: 12.720
Low
13.00
Averages
14.75
High
17.00
About RLAY
Relay Therapeutics Inc. is a clinical-stage precision medicine company. The Company’s initial focus is on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. Its Dynamo platform integrates an array of computational and experimental approaches designed to drug protein targets that have previously been intractable or inadequately addressed. The Company’s lead product candidates, such as RLY-2608. It is advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including RLY-2608. RLY-2608 is an allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alphas (PI3Kα), inhibitor in clinical development. It is the lead program in its efforts to discover and develop mutant selective inhibitors of PI3Kα.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Relay Therapeutics to Announce Q1 Earnings on May 5
- Earnings Announcement Schedule: Relay Therapeutics is set to release its Q1 2023 earnings report on May 5 after market close, with consensus EPS estimated at -$0.36 and revenue expected at $4.65 million, reflecting a significant 39.5% year-over-year decline, indicating challenges in the current market environment.
- Earnings Forecast Analysis: Over the past three months, EPS estimates have seen six upward revisions with no downward adjustments, suggesting cautious optimism among analysts regarding the company's future performance, although the overall revenue outlook remains weak, potentially impacting investor confidence.
- Market Focus: Ahead of the earnings report, Relay Therapeutics has garnered attention for its discussions on first-line breast cancer strategies and Zovegalisib triplet data, which could provide new momentum for the company's future growth prospects.
- Industry Rating Dynamics: According to Seeking Alpha's quant ratings, Relay Therapeutics and TNGX are highlighted as top picks ahead of Q1 earnings, indicating a positive market sentiment towards their potential performance, despite the current financial data warranting close scrutiny.
See More
Relay Therapeutics Advances Zovegalisib into Phase 3 Trials for Breast Cancer
- Clinical Trial Advancement: Relay Therapeutics announced plans to move Zovegalisib in combination with Pfizer's Atirmociclib into Phase 3 trials for frontline treatment of PI3Ka-mutated HR+/HER2- metastatic breast cancer, expected to commence in early 2027, showcasing the company's ongoing innovation in precision medicine.
- Trial Design Details: The randomized Phase 3 trial will evaluate the combination of Zovegalisib with Atirmociclib and an aromatase inhibitor, with median progression-free survival as the primary endpoint and overall survival as the secondary endpoint, aiming to provide more effective treatment options and enhance clinical outcomes for patients.
- Drug Supply Agreement: Pfizer has agreed to supply Atirmociclib for the experimental arm in combination with Zovegalisib, while the control arm will use palbociclib, enhancing the feasibility and efficacy of the trial and further driving the market potential of the new drug.
- Patient Response Rates: In the ongoing ReDiscover study, 34 out of 69 enrolled patients were evaluable, achieving an objective response rate of 44%, with nearly 85% of patients experiencing tumor reduction, indicating Zovegalisib's potential effectiveness in treatment and laying the groundwork for future therapeutic strategies.
See More
Zovegalisib and Atirmociclib Triplet Regimen Advances in Development
- Clinical Trial Progress: Relay Therapeutics plans to advance zovegalisib in combination with Pfizer's atirmociclib for frontline treatment of HR+/HER2- metastatic breast cancer, with a Phase 3 trial expected to initiate in early 2027, showcasing the company's strategic positioning in precision medicine.
- Efficacy Data: The combination of zovegalisib and atirmociclib demonstrated a 44% objective response rate (ORR) in median third-line patients, comparable to current standard treatments, indicating the potential effectiveness of this regimen in heavily pre-treated patients.
- Safety Assessment: Preliminary data reveal that only 3% of the 62 patients discontinued zovegalisib due to treatment-related adverse events (TRAEs), with no instances of grade 3 hyperglycemia observed, highlighting the favorable tolerability of this combination therapy, which may support long-term treatment options.
- Drug Supply Agreement: Relay Therapeutics has established a supply agreement with Pfizer to ensure the provision of atirmociclib for the Phase 3 trial, further solidifying its market position in breast cancer treatment.
See More
RELAY THERAPEUTICS INC SIGNS SUPPLY AGREEMENT WITH PFIZER FOR ATIRMOCICLIB IN PHASE 3 CLINICAL TRIAL
- Partnership Announcement: Relay Therapeutics has entered a supply agreement with Pfizer for the drug Atirmociclib.
- Clinical Trial Phase: The agreement is associated with a Phase 3 trial for Atirmociclib, indicating progress in its development.
See More
Biotech Stocks Reach New 52-Week Highs
- Relay Therapeutics Progress: Relay Therapeutics' drug candidate Zovegalisib showed promising results in clinical trials, with a 7.64% stock price increase to $14.64 on Wednesday, indicating the company's potential in treating HR+/HER2- breast cancer, with initial data expected in the first half of 2026.
- MapLight Therapeutics High: MapLight Therapeutics' stock reached $25.79 during trading yesterday, up from its IPO price of $17.00, reflecting market optimism for its drug ML-007C-MA targeting schizophrenia and Alzheimer's disease, with trial results anticipated in Q3 2026.
- Oruka Therapeutics Development: Oruka Therapeutics' ORKA-001 and ORKA-002 are in clinical trials for psoriasis, with the stock hitting $64.61, showcasing market confidence in its drugs, and significant data expected in Q2 2026.
- Spyre Therapeutics Clinical Trials: Spyre Therapeutics' stock reached $54.33 yesterday, reflecting market interest in its investigational therapies, particularly the SKYLINE trial for active ulcerative colitis, with preliminary data expected in Q3 2026.
See More
RELAY THERAPEUTICS INC.: BARCLAYS INCREASES TARGET PRICE FROM $17 TO $21
Company Overview: Relay Therapeutics is a biotechnology company focused on drug discovery and development.
Stock Price Update: Barclays has raised the target price for Relay Therapeutics' stock from $17 to $21.
See More
Relay Therapeutics to Announce Q1 Earnings on May 5
- Earnings Announcement Schedule: Relay Therapeutics is set to release its Q1 2023 earnings report on May 5 after market close, with consensus EPS estimated at -$0.36 and revenue expected at $4.65 million, reflecting a significant 39.5% year-over-year decline, indicating challenges in the current market environment.
- Earnings Forecast Analysis: Over the past three months, EPS estimates have seen six upward revisions with no downward adjustments, suggesting cautious optimism among analysts regarding the company's future performance, although the overall revenue outlook remains weak, potentially impacting investor confidence.
- Market Focus: Ahead of the earnings report, Relay Therapeutics has garnered attention for its discussions on first-line breast cancer strategies and Zovegalisib triplet data, which could provide new momentum for the company's future growth prospects.
- Industry Rating Dynamics: According to Seeking Alpha's quant ratings, Relay Therapeutics and TNGX are highlighted as top picks ahead of Q1 earnings, indicating a positive market sentiment towards their potential performance, despite the current financial data warranting close scrutiny.
See More
Relay Therapeutics Advances Zovegalisib into Phase 3 Trials for Breast Cancer
- Clinical Trial Advancement: Relay Therapeutics announced plans to move Zovegalisib in combination with Pfizer's Atirmociclib into Phase 3 trials for frontline treatment of PI3Ka-mutated HR+/HER2- metastatic breast cancer, expected to commence in early 2027, showcasing the company's ongoing innovation in precision medicine.
- Trial Design Details: The randomized Phase 3 trial will evaluate the combination of Zovegalisib with Atirmociclib and an aromatase inhibitor, with median progression-free survival as the primary endpoint and overall survival as the secondary endpoint, aiming to provide more effective treatment options and enhance clinical outcomes for patients.
- Drug Supply Agreement: Pfizer has agreed to supply Atirmociclib for the experimental arm in combination with Zovegalisib, while the control arm will use palbociclib, enhancing the feasibility and efficacy of the trial and further driving the market potential of the new drug.
- Patient Response Rates: In the ongoing ReDiscover study, 34 out of 69 enrolled patients were evaluable, achieving an objective response rate of 44%, with nearly 85% of patients experiencing tumor reduction, indicating Zovegalisib's potential effectiveness in treatment and laying the groundwork for future therapeutic strategies.
See More
Zovegalisib and Atirmociclib Triplet Regimen Advances in Development
- Clinical Trial Progress: Relay Therapeutics plans to advance zovegalisib in combination with Pfizer's atirmociclib for frontline treatment of HR+/HER2- metastatic breast cancer, with a Phase 3 trial expected to initiate in early 2027, showcasing the company's strategic positioning in precision medicine.
- Efficacy Data: The combination of zovegalisib and atirmociclib demonstrated a 44% objective response rate (ORR) in median third-line patients, comparable to current standard treatments, indicating the potential effectiveness of this regimen in heavily pre-treated patients.
- Safety Assessment: Preliminary data reveal that only 3% of the 62 patients discontinued zovegalisib due to treatment-related adverse events (TRAEs), with no instances of grade 3 hyperglycemia observed, highlighting the favorable tolerability of this combination therapy, which may support long-term treatment options.
- Drug Supply Agreement: Relay Therapeutics has established a supply agreement with Pfizer to ensure the provision of atirmociclib for the Phase 3 trial, further solidifying its market position in breast cancer treatment.
See More
RELAY THERAPEUTICS INC SIGNS SUPPLY AGREEMENT WITH PFIZER FOR ATIRMOCICLIB IN PHASE 3 CLINICAL TRIAL
- Partnership Announcement: Relay Therapeutics has entered a supply agreement with Pfizer for the drug Atirmociclib.
- Clinical Trial Phase: The agreement is associated with a Phase 3 trial for Atirmociclib, indicating progress in its development.
See More
Biotech Stocks Reach New 52-Week Highs
- Relay Therapeutics Progress: Relay Therapeutics' drug candidate Zovegalisib showed promising results in clinical trials, with a 7.64% stock price increase to $14.64 on Wednesday, indicating the company's potential in treating HR+/HER2- breast cancer, with initial data expected in the first half of 2026.
- MapLight Therapeutics High: MapLight Therapeutics' stock reached $25.79 during trading yesterday, up from its IPO price of $17.00, reflecting market optimism for its drug ML-007C-MA targeting schizophrenia and Alzheimer's disease, with trial results anticipated in Q3 2026.
- Oruka Therapeutics Development: Oruka Therapeutics' ORKA-001 and ORKA-002 are in clinical trials for psoriasis, with the stock hitting $64.61, showcasing market confidence in its drugs, and significant data expected in Q2 2026.
- Spyre Therapeutics Clinical Trials: Spyre Therapeutics' stock reached $54.33 yesterday, reflecting market interest in its investigational therapies, particularly the SKYLINE trial for active ulcerative colitis, with preliminary data expected in Q3 2026.
See More
RELAY THERAPEUTICS INC.: BARCLAYS INCREASES TARGET PRICE FROM $17 TO $21
Company Overview: Relay Therapeutics is a biotechnology company focused on drug discovery and development.
Stock Price Update: Barclays has raised the target price for Relay Therapeutics' stock from $17 to $21.
See More
